The GLOW Pregnancy Registry

Plaque psoriasis, psoriatic arthritis, and Crohn's disease are complex and chronic conditions that can be debilitating. Help future pregnant women, doctors, and researchers understand the safety of medications that can provide some relief.

Would you like to participate?
Contact the Registry today

Am I eligible?

You may be eligible if you are:

  • A resident of the United States
  • A pregnant woman diagnosed with plaque psoriasis, psoriatic arthritis, or Crohn's disease who has:
    • Used SKYRIZI® (risankizumab-rzaa) during pregnancy or just prior to pregnancy (within 20 weeks prior to conception)
    • Used other similar medications for these conditions during pregnancy or just prior to pregnancy*

*Please note: If you have used other medications similar to risankizumab, such as TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, or other IL-23 inhibitors, you may be eligible to participate. These medications include Stelara (ustekinumab), Cosentyx (secukinumab), Siliq (brodalumab), Taltz (ixekizumab), Tremfya (guselkumab), Ilumya (tildrakizumab), Enbrel (etanercept) or biosimilar (Erelzi, Eticovo, etc), Remicade (infliximab) or biosimilar (Avsola, Inflectra, Ixifi, Renflexis, etc), Humira (adalimumab) or biosimilar (Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, etc), Cimzia (certolizumab), Simponi (golimumab), ORENCIA (abatacept), or ENTYVIO (vedolizumab). If you have used any of these medications during or just prior to pregnancy, the registry staff can help determine your eligibility.

Third-party trademarks used herein are trademarks of their respective owners.

What is SKYRIZI® (risankizumab-rzaa)?

SKYRIZI® (risankizumab-rzaa) is a prescription medicine used to treat adults with:

  • Moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
  • Active psoriatic arthritis (PsA)
  • Moderate to severe Crohn's disease


SKYRIZI® (risankizumab-rzaa) may cause serious side effects, including:

  • Serious allergic reactions: Stop using SKYRIZI® and get emergency medical help right away if you get any symptoms of a serious allergic reaction.
  • Infections: SKYRIZI® may increase your risk of infections. Before starting treatment, your doctor should check you for infections and tuberculosis. Tell your doctor right away if you have an infection or symptoms of one.

Do not use SKYRIZI® if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI®.

  • Also, tell your doctor if you plan to or recently received a vaccine.
  • Liver problems in Crohn’s disease: A person with Crohn’s disease who received SKYRIZI® through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your doctor will do liver blood tests before and during treatment and may stop treatment with SKYRIZI® if you develop liver problems.
  • The most common side effects of SKYRIZI® in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.
  • The most common side effects of SKYRIZI® in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.

These are not all the possible side effects of SKYRIZI®. Call your doctor for medical advice about side effects.

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI® (risankizumab-rzaa).

How do I participate?

For more information on the GLOW Pregnancy Registry, or to learn more about your eligibility to participate, you can:

Complete the Contact Request Form here and a registry staff member will contact you

Email the registry team with your contact information at:

Call the registry team toll-free at
(hours of operation 8.30am – 5.00 pm EST Monday-Friday)

You consent that by using one of the above methods, your personal information including name, email, or telephone number will be collected to administer your registration for the electronic consent application, at the request of AbbVie Inc., the company that will collect your data. Your personal details will be shared with CISIV, the owner of the platform for eConsent, who will process your data in line with the applicable privacy laws. More details on how your personal information is going to be protected and your privacy rights will be guaranteed are included in the informed consent form.

Future pregnant women with plaque psoriasis, psoriatic arthritis, or Crohn's disease, doctors, and researchers can benefit from the information you provide to the registry.

If you are eligible and would like to participate, you will be asked to:

  1. Provide your consent (a requirement for participation in any research study)
  2. Give the registry permission to contact your healthcare provider(s) to collect information for the study

You and your healthcare provider(s) will provide information to the registry about your pregnancy and your baby’s health up to 1 year of age. This information can be provided by completing paper forms or via short phone interviews with one of the registry staff members. Only information normally documented in your medical record will be collected.

If you participate, there will be:

  • No extra doctor’s visits or additional testing
  • No changes to your existing healthcare provider(s) or care

You and your healthcare provider(s) will receive compensation for providing data to the registry.

If you are eligible and would like to participate, you will be asked to provide the following information to the registry at enrollment:

  • Basic information about yourself (e.g. race, ethnicity, education, height, and weight)
  • Information about your history of plaque psoriasis, psoriatic arthritis, or Crohn's disease

You will be paid $25 at enrollment and $25 once pregnancy or infant follow-up is completed.

Would you like to participate?

Enroll in the Registry